<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577926</url>
  </required_header>
  <id_info>
    <org_study_id>12-181</org_study_id>
    <nct_id>NCT02577926</nct_id>
  </id_info>
  <brief_title>The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia</brief_title>
  <acronym>Ruxo-BEAT</acronym>
  <official_title>Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of
      clonal hematological malignancies that are characterized by chronic myeloproliferation,
      splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms
      including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition,
      due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can
      be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as
      myelofibrosis.

      Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from
      all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells,
      while patients with essential thrombocythemia (ET) typically show a predominant expansion of
      the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently
      being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET
      have an almost normal life expectancy and often do not require specific treatment. However,
      PV- as well as ET-patients with a higher risk for complications require cytoreductive
      treatment. In addition, constitutional symptoms can be unbearable to patients even in the
      absence of bona fide high risk factors, and these patients may similarly benefit from
      antineoplastic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycythemia vera (PV) and essential thrombocythemia (ET) are classical Philadelphia-negative
      myeloproliferative neoplasms (MPN) that are characterized by an excess of cells in the
      peripheral blood, clonal bone marrow hyperplasia, and extramedullary hematopoiesis. The
      symptoms of these patients may range from asymptomatic disease to symptomatic disease that
      may significantly affect their activities of daily living, such as severe generalized
      pruritus, night sweats and fevers, erythromelalgia, bone and muscle pain, weight loss, and
      fatigue. Moreover, the patients may develop thromboembolic and hemorrhagic complications,
      transition to myelofibrosis (MF), and transformation to acute leukemia. In principle, the
      only potentially curative therapy for MPNs is allogenic stem cell transplantation (allo-SCT).
      However, due to significant transplant-associated morbidity and mortality, this therapeutic
      option is only applied in exceptional cases of ET or PV. The majority of patients do not
      qualify for allo-SCT since the risks of this treatment clearly outweigh the potential
      benefits. Moreover, even with a non-transplantation approach, patients with ET and PV have a
      life expectancy comparable to or close to healthy age-matched control persons. For patients
      with standard risk PV, phlebotomy and acetylsalicylic acid are standard of care (target
      hematocrit below 45 %), while patients with standard risk ET should receive either no
      specific treatment or acetylsalicylic acid (provided that no microvascular symptoms or
      secondary acquired von Willebrand syndrome are present).

      However, in patients who are at high risk to develop thromboembolic or hemorrhagic
      complications (high-risk patients), cytoreductive treatment is generally indicated to prevent
      these potentially life-threatening complications. In PV and ET, high risk patients are
      characterized by advanced age (&gt; 60 years) and / or a history of thromboembolic or
      hemorrhagic events {1,2,3}. In ET, a platelet count &gt; 1500 x 109/l is associated with an
      increased risk of bleeding, and thus should result in a platelet lowering treatment {2}. In
      PV, in addition to the risk-score based therapy, cytoreduction is also required in patients
      with progressive or marked myeloproliferation (leukocytosis, thrombocytosis, symptomatic
      splenomegaly, increase of frequency of phlebotomy requirement), or devastating constitutional
      symptoms {1,2,4}. In Germany, best available therapy (BAT) includes approved drugs such as
      hydroxyurea (HU; approved for both PV and ET) and anagrelide (approved for second-line
      treatment of ET) and non-approved options such as alpha-interferon, pipobroman, busulfan (in
      elderly patients), and radioactive phosphorus (32P). In rare cases, patients may also benefit
      from splenic irradiation or splenectomy.

      Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for
      the treatment of symptomatic myelofibrosis. The compound was shown to be superior to
      hydroxyurea in reducing splenomegaly and constitutional symptoms. Ruxolitinib is currently
      studied in phase 2 and phase 3 clinical trials for HU-resistant or HU-intolerant PV and ET.
      The aim of the present study is to assess the feasibility, efficacy, and safety of
      ruxolitinib treatment vs. BAT in patients with high-risk PV or -ET.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009</measure>
    <time_frame>at month 6</time_frame>
    <description>The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>at month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete response rate (CR) at month 6 as defined by Barosi et al Blood 2013 (revised ELN response criteria)</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of complete responses (CHR) at month 12 as defined by Barosi et al Blood 2009</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy as assessed by the absence of phlebotomy (Hct &lt;45%)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy as assessed by the reduction in spleen size (palpable spleen that is reduced by &gt; 50% from baseline measured by palpation and ultrasound) OR platelet count &lt; 600 x 10^9/l (ET)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving both durable absence of phlebotomy eligibility AND durable spleen volume reduction measured by palpation and ultrasound (PV) OR durable platelet count &lt;600 x 10^9/l (ET) (durable defined as &gt;3 months) {Barosi et al 2013)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of overall clinicohematologic remissions (CR + PR) according to both guidelines (Barosi et al 2009 and 2013)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Polycythemia Vera (PV)</condition>
  <condition>Essential Thrombocythemia (ET)</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best available therapy (BAT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Study drug</other_name>
    <other_name>Jakavi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT</intervention_name>
    <description>BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).</description>
    <arm_group_label>Best available therapy (BAT)</arm_group_label>
    <other_name>Control Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent and willing to comply with treatment and to follow up
             assessments and procedures

          2. &gt;18 years old

          3. Patient´s ECOG performance status: 0-2

          4. Patient must fulfill WHO 2008 diagnostic criteria for either PV or ET. PV- and
             ET-patients have to be classified as high risk according to defined criteria.

             For patients with high risk PV OR PV with indication for cytoreductive therapy due to
             progressive myeloproliferation, AT LEAST ONE of the following must be fulfilled:

               -  Age &gt;60 years

               -  Previous documented thrombosis or thromboembolism

               -  Platelet count &gt; 1500 x 10^9/L

               -  Poor tolerance of phlebotomy or frequent phlebotomy requirement

               -  Symptomatic or progressive splenomegaly

               -  Severe disease-related symptoms

               -  Progressive leukocytosis with leukocyte count &gt; 20 x 10^9/L

             For patients with high risk ET, AT LEAST ONE of the following must be fulfilled:

               -  Age &gt; 60 years

               -  Platelet count&gt; 1500 x 10^9/L

               -  Previous thrombosis or thromboembolism

               -  Previous severe hemorrhage related to ET.

          5. Patients must fulfill the following criteria regarding prior therapy:

        PV patients: Never treated with cytoreductive drugs except short- term therapy (up to 6
        weeks maximum) with ONE of the following drugs: hydroxyurea, anagrelide, or interferon
        (phlebotomy and/or aspirin are allowed) ET patients: Naïve and pretreated patients may be
        entered in this trial 7. adequate liver function, AST, and ALT ≤ 2 the institutional ULN
        value, unless directly attributable to the patient's MPN 8. creatinine clearance &gt;40ml/min
        calculated according to the modified formula of Cockcroft and Gault, eGFR, or directly
        measured after 24h-urine collection 9. ability to swallow and retain oral medication

        Exclusion Criteria:

          1. criteria for post PV-MF or post ET-MF are met

          2. previous ruxolitinib treatment

          3. history of anaphylaxis following exposure to the BAT drug of choice

          4. inadequate bone marrow reserve as demonstrated by ANC ≤ 1 x 10^9/l OR platelet count
             &lt;50 x 10^9/l

          5. known hepatitis B or C or HIV infection

          6. other severe, concurrent diseases, including tuberculosis, serious cardiac functional
             dysfunction (class III or IV), uncontrolled diabetes, uncontrolled hypertension,
             severe pulmonary disease, or major organ malfunction

          7. history of active substance or alcohol abuse within the last year

          8. Female patients who are pregnant or nursing

          9. participation in another interventional trial and/or used investigational agents or
             concurrent anticancer treatment for concomitant disease within the last 4 weeks of
             registration

         10. Any circumstances at the time the study entry that would preclude completion of the
             study or the required follow-up prohibits inclusion into this study

         11. active malignancy during the previous 3 years except for treated cervical
             intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell
             carcinoma of the skin, each with no evidence for recurrence in the past 3 years

         12. active bacterial, viral, or fungal infection

         13. medical condition requiring prolonged use of oral corticosteroids with a dose of more
             than 20 mg per day (&gt; 1 month)

         14. severe cerebral dysfunction and/or legal incapacity

         15. history of active splanchnic vein thrombosis within the last 3 months (includes
             Budd-Chiari, portal vein, splenic and mesenteric thrombosis)

         16. thyroid dysfunction which is not adequately controlled

         17. Fertile men or women of childbearing potential cannot be included unless they are:
             surgically sterile or &gt;2 years after the onset of menopause and/or willing to use a
             highly effective contraceptive method (Pearl Index &lt;1)

         18. patients who are taking any of the following prohibited medication: clarithromycin,
             telithromycin, troleandomycin, ritonavir, indinavir, saquinavir, nelfinavir,
             amprenavir, lopinavir -itraconazole, ketoconazole, voriconazole, fluconazole

         19. Patients who suffer from galactose intolerance, lack of lactose or a
             glucose-galactose-malabsortion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Koschmieder, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH University Hospital MK4</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Isfort, Dr.</last_name>
    <phone>00492418037411</phone>
    <email>sisfort@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Isfort</last_name>
    <phone>+49241803380092</phone>
    <email>sisfort@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Langfelder, Prof. Dr.</last_name>
      <phone>+49 (0)621 383 41 31</phone>
      <email>eva.lengfelder@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstanz Döhner, Prof. Dr.</last_name>
      <phone>+49 (0)731 500 45543</phone>
      <email>konstanze.doehner@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <state>Baden-Württemberg</state>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefani Parmentier, Dr.</last_name>
      <email>stefani.parmentier@rems-murr-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Schaich, Dr.</last_name>
      <email>markus.schaich@rems-murr-kliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Klausmann, Dr.</last_name>
      <email>mk@klausmann.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>III. Medizinischen Klinik des Klinikums rechts der Isar der TU München</name>
      <address>
        <city>Müchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Jost, Dr. med.</last_name>
      <email>philipp.jost@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord Medizinische Klinik 5</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marinela Augustin, Dr.</last_name>
      <phone>+49 (0) 911 398 3085</phone>
      <email>Marinela.Augustin@klinikum-nuernberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <state>Hessen</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kindler, PD Dr.</last_name>
      <phone>+49 (0)6131 17-5046</phone>
      <email>thomas.kindler@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <phone>+49 (0)228 287 17233</phone>
      <email>dominik.wolf@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47228</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Sebastian Balleisen, Dr. med.</last_name>
      <email>s.balleisen@johanniter-rheinhausen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Gattermann, Prof. Dr.</last_name>
      <email>gattermann@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Göthert Joachim, Dr.</last_name>
      <email>joachim.goethert@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Griesshammer, Prof. Dr.</last_name>
      <phone>+49 (0)571 790 4201</phone>
      <email>Martin.Griesshammer@muehlenkreiskliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Sauer, Dr.</last_name>
      <phone>+49 (0) 251 83 52818</phone>
      <email>tim.sauer@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Koschmieder, Prof. Dr.</last_name>
      <phone>00492418036102</phone>
      <email>skoschmieder@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Isfort, Dr.</last_name>
      <phone>00492418037411</phone>
      <email>sisfort@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachesen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, Dr.</last_name>
      <phone>0049 391 6713271</phone>
      <email>denise.wolleschak@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haifa K. Al-Ali, PD Dr. med.</last_name>
      <phone>0345 5574959</phone>
      <email>innere4@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hänel Mathias, PD Dr.</last_name>
      <phone>+49 (0)371 333 43045</phone>
      <email>m.haenel@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
      <phone>+49 (0)351 - 458 2583</phone>
      <email>uwe.platzbecker@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp LeCoutre, PD Dr.</last_name>
      <phone>+49 30 450 665 307</phone>
      <email>philipp.lecoutre@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg - Klinik für Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolas von Bubnoff, Prof. Dr.</last_name>
      <phone>+49 (0) 761 270-33210</phone>
      <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Schafhausen, PD Dr.</last_name>
      <phone>+49n (0)40 7410 57122</phone>
      <email>schafhausen@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Jena - Klinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07705</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Heidel, Prof. Dr.</last_name>
      <phone>+49 3641 9-324210</phone>
      <email>Florian.Heidel@med.uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

